All In Biotech

Drug Trial Radar · NCT05206773

A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease

A Randomized, Double-blind, Placebo-controlled, 12-month Phase 3 Study to Evaluate the Effect of Venglustat on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease Who Are Treatment-naïve or Untreated for at Least 6 Months

Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 122 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

122

Actual

Start

Mar 11, 2022

Primary completion

Dec 17, 2025

Study completion Jan 4, 2027

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Jan 25, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a 12-month, parallel treatment, Phase 3, double-blind, randomized, placebo-controlled study to evaluate the effect of venglustat on neuropathic and abdominal pain symptoms of Fabry disease in participants ≥16 years of age with Fabry disease who are treatment-naïve or untreated for at least 6 months. * Study visits will take place approximately every 3 months. * The double-blind period will be followed by an open-label extension (OLE) during which participants who have completed the double-blind period will be treated with venglustat for an additional 12 months or until the Common Study End of Treatment Day (CSEOTD).

Conditions

  • Fabry Disease

Interventions

  • Venglustat (GZ402671)Drug

    Pharmaceutical form: Tablet Route of administration: Oral

  • PlaceboDrug

    Pharmaceutical form: Tablet Route of administration: Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent change from baseline at 6 months in the most bothersome symptom of 3 Fabry Disease Patient-Reported Outcome (FD-PRO) items (neuropathic pain in upper extremities, neuropathic pain in lower extremities, or abdominal pain)Time frame: From baseline to 6 months
  2. Percent change from baseline at 12 months in the most bothersome symptom of 3 Fabry Disease Patient-Reported Outcome (FD-PRO) items (neuropathic pain in upper extremities, neuropathic pain in lower extremities, or abdominal pain)Time frame: From baseline to 12 months

Locations

50 sites in 21 countries. Site status is shown where the registry gives one.

  • University of Alabama -The Kirklin Clinic- Site Number : 8400011

    Birmingham, Alabama

  • David Geffen School of Medicine at UCLA- Site Number : 8400006

    Los Angeles, California

  • University of California Irvine Medical Center- Site Number : 8400019

    Orange, California

  • AdventHealth Orlando- Site Number : 8400008

    Orlando, Florida

  • Emory University School of Medicine - Atlanta- Site Number : 8400010

    Atlanta, Georgia

  • WMCHealth Advanced Physician Services- Site Number : 8400001

    Hawthorne, New York

  • Cincinnati Children's Hospital Medical Center- Site Number : 8400013

    Cincinnati, Ohio

  • UPMC Montefiore- Site Number : 8400009

    Pittsburgh, Pennsylvania

  • Renal Disease Research Institute - Dallas - Live Oak Street- Site Number : 8400012

    Dallas, Texas

  • University of Utah Health Hospital- Site Number : 8400005

    Salt Lake City, Utah

  • Lysosomal and Rare Disorders Research and Treatment Center (LDRTC)- Site Number : 8400004

    Fairfax, Virginia

  • Investigational Site Number : 0320002

    La Rioja, Argentina

  • Investigational Site Number : 0320001

    Pergamino, Buenos Aires, Argentina

  • Investigational Site Number : 0320003

    Quilmes, Buenos Aires, Argentina

  • Investigational Site Number : 0360001

    Parkville, Victoria, Australia

  • Investigational Site Number : 0400001

    Vienna, Austria

  • Instituto de Genética e Erros Inatos do Metabolismo- Site Number : 0760002

    São Paulo, Brazil

  • Hospital de Clinicas de Porto Alegre- Site Number : 0760001

    Porto Alegre, Rio Grande do Sul, Brazil

  • Investigational Site Number : 1240003

    Calgary, Alberta, Canada

  • Investigational Site Number : 1240001

    Halifax, Nova Scotia, Canada

  • Investigational Site Number : 1240005

    Toronto, Ontario, Canada

  • Investigational Site Number : 1560001

    Beijing, China

  • Investigational Site Number : 1560003

    Shanghai, China

  • Investigational Site Number : 1560004

    Taiyuan, China

  • Investigational Site Number : 1560006

    Zhengzhou, China

  • Investigational Site Number : 2080001

    Copenhagen, Denmark

  • Investigational Site Number : 2460001

    Turku, Finland

  • Investigational Site Number : 2500001

    Garches, France

  • Investigational Site Number : 2760003

    Munich, Germany

  • Investigational Site Number : 2760001

    Würzburg, Germany

  • Investigational Site Number : 3000003

    Athens, Greece

  • Investigational Site Number : 3000002

    Ioannina, Greece

  • Investigational Site Number : 3800005

    Bologna, Italy

  • Investigational Site Number : 3800001

    Naples, Napoli, Italy

  • Investigational Site Number : 3800004

    Rome, Roma, Italy

  • Investigational Site Number : 3920004

    Fukuoka, Japan

  • Investigational Site Number : 3920003

    Tokyo, Japan

  • Investigational Site Number : 4840002

    Mexico City, Mexico

  • Investigational Site Number : 4840001

    Monterrey, Nuevo León, Mexico

  • Investigational Site Number : 5780001

    Bergen, Norway

Showing 40 of 50 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.